This is the final installment of our five-part RCM Entrepreneur Rollup Strategy series. Part 1 established why debt beats PE for founders who want to build. Part 2 explained why healthcare business services companies get better financing terms than physician practices. Part 3 showed how entrepreneur-led rollups capture multiple expansion without relinquishing control. Part 4 explained how AI implementation strengthens your lender profile. This piece was supposed to close the series by explaining when ARR-based lending structures apply to hybrid RCM companies. The market changed while we were writing it.
ARR-based lending has largely fallen out of favor as a primary underwriting methodology in 2026 — and for most new originations, EBITDA is now the required basis. That is not a pessimistic observation. For profitable RCM companies — which is most mature platforms in this series — it is genuinely good news.
Key Takeaways
- According to Lincoln International’s software lending data, 0 of 8 software loans placed in January through April 2026 used ARR underwriting — all priced on EBITDA
- The February 2026 “SaaSpocalypse” — triggered by AI agents displacing enterprise software — reportedly destroyed approximately $2 trillion in software market cap and undermined the structural basis of ARR-based lending
- Most RCM companies were never pure SaaS to begin with — they are hybrid software/services businesses with real EBITDA
- Profitable RCM platforms are better positioned in the current environment, not worse — they are competing for lender attention against unprofitable SaaS companies that can no longer access ARR structures
- Revenue quality metrics still matter — but now within EBITDA-based structures, not as a substitute for them
What Happened to ARR-Based Lending — and Why It Does Not Hurt You
ARR-based lending sized debt on recurring revenue multiples rather than current earnings — in our experience, typically 1.0-2.5x ARR and in some cases as high as 4.0x. The structure rested on three assumptions: switching costs were high, subscription revenue was predictable, and growth trajectories were durable. AI agents have now challenged all three simultaneously.
The downstream effect on private credit has been severe. The Bank for International Settlements’ Quarterly Review has flagged $46.9 billion in software loans already trading at distressed levels. Morgan Stanley projects private credit default rates could reach 8% — compared to a 2-2.5% historical baseline. UBS models scenarios as high as 13%.
The companies being hurt are the ones who needed ARR lending because they had no EBITDA. Most RCM companies do not fit that profile — they are hybrid software/services businesses with operational cash flows, contracted recurring revenue, and real EBITDA. They did not depend on ARR structures, and they are not exposed to the same disruption risk.
The ARR Lending Reset — What Changed
| Dimension | ARR Lending (2023-2024 Peak) | Current Market (2026) |
|---|---|---|
| Underwriting basis | Recurring revenue / ARR multiples | EBITDA / cash flow profitability |
| Typical leverage | 1.0-2.5x ARR (up to 4.0x in select cases) | 4-6x EBITDA |
| Lender requirement | ARR growth 20%+, NRR 110%+ | Minimum $5MM+ EBITDA; profitability required |
| Default environment | Sub-2% historical defaults | Elevated — projected 8%+ (Morgan Stanley) |
| Revenue quality lens | Growth rate was primary metric | Retention and churn primary; growth secondary |
| Healthcare RCM positioning | Could access ARR structures if 50%+ software revenue | Better positioned — real EBITDA + recurring revenue quality = premium within EBITDA structures |
The shift changes who competes for lender attention. Profitable RCM platforms are no longer in the same queue as unprofitable SaaS companies. Lenders who were stretching into ARR structures 12 months ago now require EBITDA as the price of admission — and mature RCM operators can deliver that.
Does Revenue Quality Still Matter in an EBITDA-Only World?
The revenue quality framework from earlier versions of this series still applies. It just operates within a different structure.
Lenders who remain active in software-adjacent healthcare lending are laser-focused on retention and churn — not as qualifiers for ARR structures, but as risk adjustments within EBITDA-based underwriting. A company with 95% gross retention and NRR above 110% commands better terms, higher leverage multiples, and more flexible covenants within an EBITDA facility than a company with equivalent EBITDA and 85% retention.
There is a related concern worth addressing directly: the same lenders who are pulling back from ARR-based SaaS lending are also asking whether AI will displace healthcare services firms — including RCM companies. The concern is understandable. But as we covered in Part 4 of this series, AI in RCM is a productivity tool, not a replacement. It automates denial prediction, coding, and contract analysis — it does not replicate the clinical judgment, regulatory expertise, and payor relationship management that drive retention. In our experience, RCM companies that have invested in AI are positioning themselves for margin improvement and operational leverage — which is exactly what EBITDA-focused lenders want to see.
According to the Bank for International Settlements’ Quarterly Review, companies classified as “healthcare” or “business services” may be fundamentally software-driven — lenders are looking through labels to understand true revenue composition and durability. That scrutiny benefits RCM companies with genuine clinical integration, because the answer to “is AI going to disrupt your revenue?” is demonstrably different for embedded healthcare platforms than for horizontal SaaS.
According to Bessemer Venture Partners’ health tech benchmarks, NRR of 110-120% is standard for healthcare SaaS companies commanding premium terms. Industry benchmarks suggest median B2B SaaS monthly churn runs in the 3%-5% range. For RCM companies, the relevant question is whether your retention metrics position you favorably within an EBITDA structure — and if they do, they unlock better pricing, higher leverage, and more borrower-friendly covenants.
The question has changed. It is no longer “do you have enough ARR to qualify for ARR lending?” It is “do your retention metrics demonstrate the sustainability of your cash flows?” Strong retention tells lenders that today’s EBITDA is durable — and durable EBITDA gets better terms.
Why Healthcare RCM Is Better Positioned Than Horizontal SaaS
The same AI disruption that collapsed ARR-based lending for horizontal SaaS is not an existential threat to deeply integrated RCM platforms. This is a meaningful distinction.
| Factor | Horizontal SaaS | Healthcare RCM |
|---|---|---|
| AI disruption risk | Existential — agents replace per-seat tools | Operational — AI improves RCM workflows, not replaces them |
| Switching costs | Declining as AI lowers migration barriers | High — clinical integration, regulatory compliance, EHR embedding |
| Revenue model | Per-seat subscriptions under pressure | Hybrid software + services with contracted relationships |
| EBITDA profile | Many unprofitable (relied on ARR lending) | Most mature platforms are profitable |
| Lender appetite (2026) | Severely reduced; spreads widened 100+ bps | Stable to improving for profitable platforms |
According to AGS Health’s 2026 research, 63% of providers have introduced AI into RCM workflows. That adoption pattern reflects something important: AI is a tool that improves RCM operations — denial prediction, coding automation, contract analysis — not a technology that replaces RCM services entirely. The clinical judgment, regulatory knowledge, and payor relationship expertise embedded in mature RCM platforms have not been automated away.
According to Oliver Wyman’s healthcare services research, the RCM outsourcing market is projected to nearly double within the next four years. Demand is not going away. EHR vendors including Epic and Oracle Health are building native RCM capabilities, which creates some disintermediation risk — but deeply integrated RCM platforms with clinical workflow embedding have genuine switching costs that are not easily replicated.
For RCM companies that followed the AI implementation guidance in Part 4 of this series, those investments now serve a dual purpose: improving operational margins and demonstrating to lenders that your platform uses AI as a productivity multiplier, not a survival mechanism.
The Series Conclusion
The arc from Parts 1 through 4 holds. Debt beats PE for founders who want to build. Now is still the time to build, not sell. AI implementation still strengthens your lender profile and valuation trajectory.
Part 5’s message has been updated by the market: the financing structure most relevant to RCM companies has changed, but the strategy has not. EBITDA-based lending was always the foundation for mature RCM platforms. The collapse of ARR-based lending simply removes the distraction — and removes the competition.
Lenders who were underwriting on ARR multiples 12 months ago now require EBITDA. If your RCM platform has real profitability, that is your competitive advantage in this market. You are not competing with unprofitable SaaS companies for lender attention anymore. You are competing within a pool of profitable, cash-flowing businesses — and RCM’s recurring revenue characteristics, clinical switching costs, and AI-enhanced margins give you a strong position in that pool.
CAPX has structured debt for software-enabled healthcare companies navigating this market. In our experience, the RCM platforms with the clearest path to capital in 2026 are the ones with documented EBITDA, contractual recurring revenue, and an articulated AI strategy — the same profile this series has been building toward from the beginning.
If you have been following this series and want to understand what structure fits your model in the current environment, we are happy to start with a conversation. No pitch required. Reach out at info@capx.io or contact us here.
